Sarcopenia and Ageing.
Level 5 - mechanism / opinion, no new human data
Narrative review / book chapter without systematic review methodology
PubMed 37120466 · doi:10.1007/978-3-031-26576-1_6
What was done
This book chapter reviews literature on age-related sarcopenia across three domains: (1) clinical screening, diagnostic criteria, and consensus definitions, noting its ICD-10-CM classification (M62.84); (2) cellular and tissue-level pathogenesis, with emphasis on mitochondrial dysfunction, intramuscular fat infiltration, and neuromuscular junction deterioration; and (3) interventions focused on physical exercise and nutritional supplementation.
What was found
The abstract reports no experimental data, effect sizes, or quantitative outcome metrics. It notes descriptive background that muscles and bones account for approximately 55–60% of body weight, and outlines sarcopenia as the progressive loss of skeletal muscle mass and strength associated with adverse outcomes.
Why it matters
It provides an overview of clinical diagnosis criteria, pathophysiological mechanisms, and exercise or nutrition interventions for age-related muscle loss.
Limits
This is a narrative review chapter lacking a systematic search protocol, quantitative synthesis, sample size, or original clinical trial data.
Cited by
- context Aging and metabolic dysfunction lead to fatty infiltration of skeletal muscle, which causes degradation and atrophy of neuromuscular junctions and nerves.